Long
HZNP vs DEPO
HZNP, a strong growth specialty biopharmaceutical company, Its shares have been in a down trend lately which could blame the overall weakness in the market and the action between the firm and DEPO which is their target of acquisition.
I personally like HZNP due to its pipeline and strong growth. The latest quarterly earning showed that its growth was accelerated.
However, interestingly enough, the share did not perform well post earning release. But overall target price from many analysts is in the range of $37-$40 per share.
Even without Depomed acquisition, I still believe that HZNP will continue to grow strongly due to its broad pipeline and its novelty drug for orphan disease.
Risk Reward Ratio calculation
As I mention that most analysts' TP is about $37-40 so I will use $37.
Yesterday (9/17/2018) HZNP share went up significantly with tremendous volume (Fed minutes did play huge role here) but it did not fade downward like SPX or most of stocks. Hence, signal a pocket pivot buypoint.
Entry 31.16
Exit at 8% cutloss 28.67
TP 37
RRR = 0.4
I personally like HZNP due to its pipeline and strong growth. The latest quarterly earning showed that its growth was accelerated.
However, interestingly enough, the share did not perform well post earning release. But overall target price from many analysts is in the range of $37-$40 per share.
Even without Depomed acquisition, I still believe that HZNP will continue to grow strongly due to its broad pipeline and its novelty drug for orphan disease.
Risk Reward Ratio calculation
As I mention that most analysts' TP is about $37-40 so I will use $37.
Yesterday (9/17/2018) HZNP share went up significantly with tremendous volume (Fed minutes did play huge role here) but it did not fade downward like SPX or most of stocks. Hence, signal a pocket pivot buypoint.
Entry 31.16
Exit at 8% cutloss 28.67
TP 37
RRR = 0.4
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.